Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Survey: More Research Patents, Start-Ups in 2016

A survey of universities and other institutions shows the number of patent filings and new start-up companies resulting from federally-funded research climbed in 2016. . . . → Read More: Survey: More Research Patents, Start-Ups in 2016

Infographic – Patenting Among Top Tech Companies

CB Insights compiled a recent research brief with a chart showing where the top five technology companies — Google, Amazon, Facebook, Apple, and Microsoft — are placing their bets with new patent applications. . . . → Read More: Infographic – Patenting Among Top Tech Companies

Bayer Acquiring Therapeutic Peptides in $1.1B+ Deal

Bayer AG, the global drug maker and agricultural chemical company, is partnering with a Japanese biologics enterprise to discover a series of peptides for therapies. . . . → Read More: Bayer Acquiring Therapeutic Peptides in $1.1B+ Deal

Biotech Licenses Mayo Clinic Microbiome Research

A biotechnology company developing therapies with specialized gut microbes is licensing research from the Mayo Clinic on these microbes’ effects with autoimmune diseases. . . . → Read More: Biotech Licenses Mayo Clinic Microbiome Research

Zymeworks, Janssen in $1.45B Antibody Licensing Deal

Janssen Biotech, a division of drug maker Johnson & Johnson, is acquiring technologies that make it possible to create synthetic antibodies that hit multiple targets. . . . → Read More: Zymeworks, Janssen in $1.45B Antibody Licensing Deal

Sanofi Acquires Multiple Sclerosis Drug in $800M Deal

Drug maker Sanofi is licensing a drug candidate from Principia Biopharma Inc. designed to treat multiple sclerosis, an autoimmune condition affecting the brain and nervous system. . . . → Read More: Sanofi Acquires Multiple Sclerosis Drug in $800M Deal

Start-Up Formed to Develop Non-Opioid Pain Drugs

A new enterprise is being formed to develop non-addictive drugs for chronic pain that use different biochemical processes than opioid pain relievers. . . . → Read More: Start-Up Formed to Develop Non-Opioid Pain Drugs

RNA Meds Companies Partner on Human, Animal Vaccines

Synthetic Genomics Inc. and Arcturus Therapeutics Inc. are collaborating on longer-lasting and more robust RNA therapies and vaccines for humans and animals. . . . → Read More: RNA Meds Companies Partner on Human, Animal Vaccines

Univ. Lab, Company Broaden Bacterial Vaccine Impact

Researchers from University at Buffalo and a campus spin-off enterprise devised a way to expand the scope of anti-bacterial vaccines, as shown in tests with lab animals. . . . → Read More: Univ. Lab, Company Broaden Bacterial Vaccine Impact

Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal

Drug maker Eli Lilly and Company and biotechnology company CureVac AG agreed to develop a series of cancer immunotherapies based on CureVac’s messenger RNA technology. . . . → Read More: Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal